Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | FUCA1 | P04066 | 3/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18588970 | 0.74 | — | — | |
| SCHEMBL20960909 | 0.74 | — | — | |
| SCHEMBL19594887 | 0.72 | — | — | |
| SCHEMBL2571064 | 0.71 | CYP2C9 (0.38) | CYP2C9 | |
| Methyl Alcohol SCHEMBL9767526 | 0.71 | — | — | |
| SCHEMBL4959982 | 0.71 | CYP2C9 (0.38) | CYP2C9FUCA1SI | |
| SCHEMBL372857 | 0.70 | — | — | |
| SCHEMBL8350911 | 0.67 | CYP2C9 (0.35) | CYP2C9FUCA1 | |
| SCHEMBL2621344 | 0.67 | CYP2C9 (0.35) | CYP2C9FUCA1 | |
| SCHEMBL10158374 | 0.67 | CYP2C9 (0.35) | CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037357-B2 | Compounds for activating invariant natural killer T-cells and methods of use in eliminating inflammatory senescent cells | DECIDUOUS THERAPEUTICS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240025936-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | DECIDUOUS THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037357-B2 | Compounds for activating invariant natural killer T-cells and methods of use in eliminating inflammatory senescent cells | IL2, IL4, PBK | CYP2C9 4868/4885FUCA1 1437/4885SI 470/4885 |
| US-20240025936-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | IL2, PBK, IL4 | CYP2C9 4873/4885FUCA1 1068/4885SI 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.